L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia

Research output: Contribution to journalArticle

Abstract

We have reported previously that conjugated estrogens that are effective in shortening the prolonged bleeding time in uremic patients are also effective on bleeding time in a rat model of uremia. Using such a rat model we have recently demonstrated that nitric oxide (NO), an endothelium-derived vasodilator, is involved in mediating the bleeding tendency of uremia. With the present study we wanted to investigate whether conjugated estrogen mixture or its active component, 17β-estradiol, reduce uremic bleeding by interfering with the NO pathway. Our results showed that the shortening effect of conjugated estrogen and 17β-estradiol on bleeding time of uremic rats was completely reversed by giving the animals the NO precursor L-arginine, but not D-arginine, which is not a precursor of NO. Dexamethasone which at variance to progesterone inhibits the process of induction of NO-forming enzyme, shortened the prolonged bleeding time of uremic rats within 4 hours from injection. This effect was eliminated by L-arginine but not D-arginine administration. The glucocorticoid receptor antagonist cortexolone prevented the shortening of bleeding time induced by dexamethasone, suggesting that a receptor-mediated mechanism is involved in the hemostatic effect of dexamethasone as previously reported for estrogens. Unlike conjugated estrogens and dexamethasone, progesterone had no effect on bleeding time. All these findings would indicate that the effect of estrogens and dexamethasone on primary hemostasis in uremia might be mediated by changes in NO synthetic pathway.

Original languageEnglish
Pages (from-to)479-483
Number of pages5
JournalLaboratory Investigation
Volume65
Issue number4
Publication statusPublished - 1991

Fingerprint

Bleeding Time
Uremia
Arginine
Conjugated (USP) Estrogens
Nitric Oxide
Estrogens
Dexamethasone
Progesterone
Estradiol
Cortodoxone
Hemorrhage
Glucocorticoid Receptors
Hemostatics
Hemostasis
Vasodilator Agents
Injections
Enzymes

Keywords

  • 17β-Estradiol
  • Conjugated estrogens
  • Glucocorticoids
  • L-arginine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{687d31957edc4c239bd54492ffbd22fa,
title = "L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia",
abstract = "We have reported previously that conjugated estrogens that are effective in shortening the prolonged bleeding time in uremic patients are also effective on bleeding time in a rat model of uremia. Using such a rat model we have recently demonstrated that nitric oxide (NO), an endothelium-derived vasodilator, is involved in mediating the bleeding tendency of uremia. With the present study we wanted to investigate whether conjugated estrogen mixture or its active component, 17β-estradiol, reduce uremic bleeding by interfering with the NO pathway. Our results showed that the shortening effect of conjugated estrogen and 17β-estradiol on bleeding time of uremic rats was completely reversed by giving the animals the NO precursor L-arginine, but not D-arginine, which is not a precursor of NO. Dexamethasone which at variance to progesterone inhibits the process of induction of NO-forming enzyme, shortened the prolonged bleeding time of uremic rats within 4 hours from injection. This effect was eliminated by L-arginine but not D-arginine administration. The glucocorticoid receptor antagonist cortexolone prevented the shortening of bleeding time induced by dexamethasone, suggesting that a receptor-mediated mechanism is involved in the hemostatic effect of dexamethasone as previously reported for estrogens. Unlike conjugated estrogens and dexamethasone, progesterone had no effect on bleeding time. All these findings would indicate that the effect of estrogens and dexamethasone on primary hemostasis in uremia might be mediated by changes in NO synthetic pathway.",
keywords = "17β-Estradiol, Conjugated estrogens, Glucocorticoids, L-arginine",
author = "C. Zoja and M. Noris and D. Corna and G. Vigano and N. Perico and {De Gaetano}, G. and G. Remuzzi",
year = "1991",
language = "English",
volume = "65",
pages = "479--483",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - L-Arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia

AU - Zoja, C.

AU - Noris, M.

AU - Corna, D.

AU - Vigano, G.

AU - Perico, N.

AU - De Gaetano, G.

AU - Remuzzi, G.

PY - 1991

Y1 - 1991

N2 - We have reported previously that conjugated estrogens that are effective in shortening the prolonged bleeding time in uremic patients are also effective on bleeding time in a rat model of uremia. Using such a rat model we have recently demonstrated that nitric oxide (NO), an endothelium-derived vasodilator, is involved in mediating the bleeding tendency of uremia. With the present study we wanted to investigate whether conjugated estrogen mixture or its active component, 17β-estradiol, reduce uremic bleeding by interfering with the NO pathway. Our results showed that the shortening effect of conjugated estrogen and 17β-estradiol on bleeding time of uremic rats was completely reversed by giving the animals the NO precursor L-arginine, but not D-arginine, which is not a precursor of NO. Dexamethasone which at variance to progesterone inhibits the process of induction of NO-forming enzyme, shortened the prolonged bleeding time of uremic rats within 4 hours from injection. This effect was eliminated by L-arginine but not D-arginine administration. The glucocorticoid receptor antagonist cortexolone prevented the shortening of bleeding time induced by dexamethasone, suggesting that a receptor-mediated mechanism is involved in the hemostatic effect of dexamethasone as previously reported for estrogens. Unlike conjugated estrogens and dexamethasone, progesterone had no effect on bleeding time. All these findings would indicate that the effect of estrogens and dexamethasone on primary hemostasis in uremia might be mediated by changes in NO synthetic pathway.

AB - We have reported previously that conjugated estrogens that are effective in shortening the prolonged bleeding time in uremic patients are also effective on bleeding time in a rat model of uremia. Using such a rat model we have recently demonstrated that nitric oxide (NO), an endothelium-derived vasodilator, is involved in mediating the bleeding tendency of uremia. With the present study we wanted to investigate whether conjugated estrogen mixture or its active component, 17β-estradiol, reduce uremic bleeding by interfering with the NO pathway. Our results showed that the shortening effect of conjugated estrogen and 17β-estradiol on bleeding time of uremic rats was completely reversed by giving the animals the NO precursor L-arginine, but not D-arginine, which is not a precursor of NO. Dexamethasone which at variance to progesterone inhibits the process of induction of NO-forming enzyme, shortened the prolonged bleeding time of uremic rats within 4 hours from injection. This effect was eliminated by L-arginine but not D-arginine administration. The glucocorticoid receptor antagonist cortexolone prevented the shortening of bleeding time induced by dexamethasone, suggesting that a receptor-mediated mechanism is involved in the hemostatic effect of dexamethasone as previously reported for estrogens. Unlike conjugated estrogens and dexamethasone, progesterone had no effect on bleeding time. All these findings would indicate that the effect of estrogens and dexamethasone on primary hemostasis in uremia might be mediated by changes in NO synthetic pathway.

KW - 17β-Estradiol

KW - Conjugated estrogens

KW - Glucocorticoids

KW - L-arginine

UR - http://www.scopus.com/inward/record.url?scp=0025723449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025723449&partnerID=8YFLogxK

M3 - Article

C2 - 1656142

AN - SCOPUS:0025723449

VL - 65

SP - 479

EP - 483

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 4

ER -